Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.49 |
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.40 |
| ▸ | TMPRSS15 | P98073 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20008627 | 0.82 | PRSS1 (0.47) | KMT2AMAPTMEN1TDP1ATM | |
| SCHEMBL20012325 | 0.81 | NR1H4 (0.43) | KMT2AMAPTMEN1NR1H4TDP1 | |
| SCHEMBL6674203 | 0.79 | ESR1 (0.57) | KMT2AMAPTMEN1NR1H4TDP1 | |
| SCHEMBL4335496 | 0.78 | NR1H4 (0.50) | KMT2AMAPTMEN1NR1H4TDP1 | |
| SCHEMBL18720227 | 0.76 | KMT2A (0.44) | KMT2AMAPTMEN1TDP1L3MBTL1 | |
| SCHEMBL11392449 | 0.76 | MAPT (0.49) | KMT2AMAPTMEN1TDP1ATM | |
| SCHEMBL8844966 | 0.76 | TDP1 (0.60) | KMT2AMAPTMEN1TDP1ATM | |
| Benzamide SCHEMBL21771957 | 0.76 | TDP1 (0.54) | KMT2AMAPTMEN1NR1H4TDP1 | |
| Benzamide SCHEMBL21771961 | 0.76 | PARP10 (0.49) | KMT2AMAPTMEN1TDP1ATM | |
| SCHEMBL21819813 | 0.76 | ALDH1A1 (0.48) | KMT2AMAPTMEN1L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11154549-B2 | Opioid compositions resistant to overdose and abuse | ELYSIUM THERAPEUTICS, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| US-20200093817-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2020-03-26 | — | — | US | disclosed |
| US-10335406-B2 | Opioid compositions resistant to overdose and abuse | ELYSIUM THERAPEUTICS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180085366-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20180085366-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200093817-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRD1 | KMT2A 1946/4885MAPT 922/4885MEN1 4875/4885 |
| US-20180085366-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRD1 | KMT2A 1946/4885MAPT 922/4885MEN1 4875/4885 |
| US-10335406-B2 | Opioid compositions resistant to overdose and abuse | OPRM1, OPRK1, OPRD1 | KMT2A 1946/4885MAPT 922/4885MEN1 4875/4885 |
| US-11154549-B2 | Opioid compositions resistant to overdose and abuse | OPRM1, OPRK1, OPRD1 | KMT2A 1946/4885MAPT 922/4885MEN1 4875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.